Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BioPharma Credit PLC (BOPCF)
Exeter, GB
Operating as an investment trust, BioPharma Credit PLC primarily allocates its capital to debt instruments that generate interest. The security for these investments is provided by royalties or other cash streams originating from the commercial sale of approved life sciences products. This company was established in 2016 and its headquarters are situated in Exeter, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +6.21% | -1.68% | +5.85% | +1.22% | +2.69% | +4.82% | +2.64% | -3.16% | -17.35% | -17.35% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Asset Management: +17.4%+12.7% Q4'25: +10.2% (vs Q4'23)
-
EPS growth Asset Management: +22.7%+10.0% Q4'25: +75.7% (vs Q4'23)
-
FCF margin FCF growth · Asset Management: +27.7%+77.5% Q4'25: +90.9% (vs Q4'23)
-
EBIT margin Asset Management: +50.6%+92.6% ★ Q4'25: +90.5% (vs Q4'23)
-
ROIC Asset Management: +6.5%+11.4% ★ Q4'25: +20.1% (vs Q4'23)
-
Share dilution Asset Management: +0.0%-6.8% ★ Q4'25: -13.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Asset Management: -0.03×0.00× ★ Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 4/5 | 3/5 |
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
No beneficial ownership filings recorded.
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | AUBREY CAPITAL MANAGEMENT LTD | 2.95M -101.0K (-3.3%) | 2.71M -30.4K (-1.1%) | 0.26% -0.009 pp | 1.07% +0.203 pp | USD0.91 -6.6% | 14 qtrs — |
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Martin Friedman | Investment Manager | — | male |
| Pablo Legorreta | Investment Manager | — | male |
| Pedro Gonzalez de Cosio | Investment Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BOPCF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
